Arcus Biosciences, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Arcus Biosciences, Inc. RCUS.N reported a quarterly adjusted loss of 100 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.27. The mean expectation of fourteen analysts for the quarter was for a loss of 90 cents per share. Wall Street expected results to range from -100 cents to -77 cents per share.

• Revenue fell 65.4% to $9.00 million from a year ago; analysts expected $8.31 million.

• Arcus Biosciences, Inc.'s reported EPS for the quarter was a loss of $1.00​.

• The company reported a quarterly loss of $128 million.

• Arcus Biosciences, Inc. shares had fallen by 26.8% this quarter and lost 20.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Arcus Biosciences, Inc. is $42.00, about 54% above its last closing price of $19.31

This summary was machine generated from LSEG data November 4 at 09:59 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)